Professor Peter W.M Johnson CBE MD FRCP FMedSci is Chairman of Oncimmune’s Scientific Board. Peter is an expert in the development and assessment of Immuno-Oncology, is Professor of Medical Oncology in Southampton, CRUK’s Chief Clinician and Director of the Francis Crick Institute Cancer Research Network. Professor Johnson trained in Medical Oncology at St. Bartholomew’s Hospital in London, where his research developed molecular techniques to detect very low levels of lymphoma in blood. Professor Johnson was awarded a CBE in the HM Queen Elizabeth II’s 90thbirthday honours list for services to medical research.
The Scientific Board is responsible for advising Oncimmune on its scientific strategy. It consists of some of the world’s leading experts in cancer prevention and diagnosis, and in the science of immunoassays. Members of the Scientific Board also take on responsibility for overseeing and guiding key research and development projects.
Dr. Richard M Roope MA FRCGP is a General Practitioner and UK Clinical Lead for Cancer at the Royal College of General Practitioners. He is a Senior Clinical Advisor (Prevention and Early Diagnosis) at Cancer Research UK, and a member of the National Cancer Advisory Group. Dr. Roope trained at Cambridge University and the University of London graduating in 1987 with a Bachelor of Medicine and Surgery degree. In 2015, he was elected to Fellowship of the RCGP for contributions to Cancer Management.
Dr. Nora Pashayan MD MSc MSt PhD FFPH is a Clinical Reader in Applied Health Research at University College London, a qualified GP and Honorary Consultant in Public Health at University College London Hospitals, as well as a member of the Breast Cancer Now Scientific Advisory Board. She received a MSc in Epidemiology from London School of Hygiene and Tropical Medicine and MSt in Public Health and PhD from the University of Cambridge before commencing a research career at the University of Cambridge, focusing on early detection, particularly in risk-stratified screening of cancer.
Professor Ola S Winqvist MD PhD is a Professor of Cellular Immunotherapy at the Karolinska Institute and Senior Consultant in Clinical Immunology at the Karolinska University Hospital. Professor Winqvist received his medical qualification in 1991 at the University of Uppsala. He then went on to achieve a PhD, focusing on experimental medicine and autoantigens in Addison’s disease. He held a post-doctoral position at the Scripps Research Institute in California for three years and was Chairman of the Swedish Clinical Immunology Society until 2017.